TY - JOUR
T1 - Staphylococcus aureus Skin and Soft Tissue Infection Recurrence Rates in Outpatients
T2 - A Retrospective Database Study at 3 US Medical Centers
AU - Vella, Venanzio
AU - Galgani, Ilaria
AU - Polito, Letizia
AU - Arora, Ashwani Kumar
AU - Creech, C. Buddy
AU - David, Michael Z.
AU - Lowy, Franklin D.
AU - Macesic, Nenad
AU - Ridgway, Jessica P.
AU - Uhlemann, Anne Catrin
AU - Bagnoli, Fabio
N1 - Funding Information:
GlaxoSmithKline Biologicals S.A. funded this work, was involved in all stages of the study conduct and analysis, and took charge of all costs associated with the developing and publishing of the manuscript. Potential conflicts of interest. V. V., I. G., A. K. A., and F. B. are employees and L. P. is a former employee of the GSK group of companies and have no nonfinancial interest to declare. V. V. and F. B. hold shares in the GSK group of companies. F. B. holds pending and issued patents (WO/2019/158537, WO/2015/144691, WO/2015/144653, WO/2015/144655, WO/2014/033190, WO/2014/033191, WO/2014/033192, WO/2014/033193, WO/2013/030378, WO/2010/119343) on Staphylococcus aureus vaccine formulations. C. B. C. received grant support, paid to his institution from the GSK group of companies; received grant support and personal fees from the GSK group of companies and Pfizer for consulting in staphylococcal vaccine development; and personal fees from Horizon Pharma, Astellas, Karius, Inc, and Premier Healthcare for consulting. C. B. C. holds a pending patent (16491271) on staphylococcal antibodies. A. C. U. received grant support from the GSK group of companies and Merck. M. Z. D. received grant support from the GSK group of companies and personal fees from Baxter for consulting. F. D. L. holds royalties for UptoDate as topic writer and section editor and received grant support from the National Institute of Allergy and Infectious Diseases (R21 AI152046) and the GSK group of companies. J. P. R. received grant support from the GSK group of companies and Gilead Sciences. N. M. received grant support from the Australian National Health and Medical Research Council (postgraduate scholarship APP1169514 and EL1 Investigator grant APP1176324) and from the GSK group of companies. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Publisher Copyright:
© 2020 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Background: Staphylococcus aureus skin and soft tissue infections (SA-SSTIs) are common in healthcare and community settings, and recurrences occur at variable frequency, even after successful initial treatment. Knowing the exact burden and timing of recurrent disease is critical to planning and evaluating interventions to prevent recurrent SSTIs. Methods: In this retrospective study, SSTI cases in patients aged ≥18 years at 3 US medical centers (Columbia, Chicago, Vanderbilt) between 2006 and 2016 were analyzed according to a biennial cohort design. Index SSTIs (with or without key comorbidities), either microbiologically confirmed to be SA-SSTI or not microbiologically tested (NMT-SSTI), were recorded within 1 calendar year and followed up for 12 months for recurrent infections. The number of index cases, proportion of index cases with ≥1 recurrence(s), time to first recurrence, and number of recurrences were collected for both SA-SSTI and NMT-SSTI events. Results: In the most recent cohorts, 4755 SSTI cases were reported at Columbia, 2873 at Chicago, and 6433 at Vanderbilt. Of these, 452, 153, and 354 cases were confirmed to be due to S. aureus. Most cases were reported in patients without key comorbidities. Across centers, 16.4%-19.0% (SA-SSTI) and 11.0%-19.2% (NMT-SSTI) of index cases had ≥1 recurrence(s). In patients without key comorbidities, more than 60% of index SSTIs with recurrences had only 1 recurrence, half of which occurred in the first 3 months following primary infection. Conclusions: SA-SSTI recurrences are common among healthy adults and occur in at least 1 in 6 individuals during the 1 year following the primary event.
AB - Background: Staphylococcus aureus skin and soft tissue infections (SA-SSTIs) are common in healthcare and community settings, and recurrences occur at variable frequency, even after successful initial treatment. Knowing the exact burden and timing of recurrent disease is critical to planning and evaluating interventions to prevent recurrent SSTIs. Methods: In this retrospective study, SSTI cases in patients aged ≥18 years at 3 US medical centers (Columbia, Chicago, Vanderbilt) between 2006 and 2016 were analyzed according to a biennial cohort design. Index SSTIs (with or without key comorbidities), either microbiologically confirmed to be SA-SSTI or not microbiologically tested (NMT-SSTI), were recorded within 1 calendar year and followed up for 12 months for recurrent infections. The number of index cases, proportion of index cases with ≥1 recurrence(s), time to first recurrence, and number of recurrences were collected for both SA-SSTI and NMT-SSTI events. Results: In the most recent cohorts, 4755 SSTI cases were reported at Columbia, 2873 at Chicago, and 6433 at Vanderbilt. Of these, 452, 153, and 354 cases were confirmed to be due to S. aureus. Most cases were reported in patients without key comorbidities. Across centers, 16.4%-19.0% (SA-SSTI) and 11.0%-19.2% (NMT-SSTI) of index cases had ≥1 recurrence(s). In patients without key comorbidities, more than 60% of index SSTIs with recurrences had only 1 recurrence, half of which occurred in the first 3 months following primary infection. Conclusions: SA-SSTI recurrences are common among healthy adults and occur in at least 1 in 6 individuals during the 1 year following the primary event.
KW - antimicrobial resistance
KW - methicillin-resistant Staphylococcus aureus
KW - skin and soft tissue infection (SSTI)
KW - SSTI recurrence
KW - Staphylococcus aureus
UR - http://www.scopus.com/inward/record.url?scp=85103396261&partnerID=8YFLogxK
U2 - 10.1093/cid/ciaa1717
DO - 10.1093/cid/ciaa1717
M3 - Review Article
C2 - 33197926
AN - SCOPUS:85103396261
SN - 1058-4838
VL - 73
SP - E1045-E1053
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 5
ER -
